Radiomic prediction of mutation status based on MR imaging of lung cancer brain metastases.
Adult
Aged
Algorithms
Anaplastic Lymphoma Kinase
/ genetics
Area Under Curve
Brain Neoplasms
/ diagnostic imaging
DNA Mutational Analysis
ErbB Receptors
/ genetics
Female
Humans
Lung Neoplasms
/ diagnostic imaging
Magnetic Resonance Imaging
Male
Middle Aged
Mutation
Neoplasm Metastasis
/ pathology
Prognosis
Proto-Oncogene Proteins p21(ras)
/ genetics
Retrospective Studies
Brain metastases
Lung cancer
Mutation
Predictive modeling
Radiomics
Journal
Magnetic resonance imaging
ISSN: 1873-5894
Titre abrégé: Magn Reson Imaging
Pays: Netherlands
ID NLM: 8214883
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
28
12
2019
revised:
20
02
2020
accepted:
05
03
2020
pubmed:
18
3
2020
medline:
16
12
2020
entrez:
18
3
2020
Statut:
ppublish
Résumé
Lung cancer metastases comprise most of all brain metastases in adults and most brain metastases are diagnosed by magnetic resonance (MR) scans. The purpose of this study was to conduct an MR imaging-based radiomic analysis of brain metastatic lesions from patients with primary lung cancer to classify mutational status of the metastatic disease. We retrospectively identified lung cancer patients with brain metastases treated at our institution between 2009 and 2017 who underwent genotype testing of their primary lung cancer. Brain MR Images were used for segmentation of enhancing tumors and peritumoral edema, and for radiomic feature extraction. The most relevant radiomic features were identified and used with clinical data to train random forest classifiers to classify the mutation status. Of 110 patients in the study cohort (mean age 57.51 ± 12.32 years; M: F = 37:73), 75 had an EGFR mutation, 21 had an ALK translocation, and 15 had a KRAS mutation. One patient had both ALK translocation and EGFR mutation. Majority of radiomic features most relevant for mutation classification were textural. Model building using both radiomic features and clinical data yielded more accurate classifications than using either alone. For classification of EGFR, ALK, and KRAS mutation status, the model built with both radiomic features and clinical data resulted in area-under-the-curve (AUC) values based on cross-validation of 0.912, 0.915, and 0.985, respectively. Our study demonstrated that MR imaging-based radiomic analysis of brain metastases in patients with primary lung cancer may be used to classify mutation status. This approach may be useful for devising treatment strategies and informing prognosis.
Identifiants
pubmed: 32179095
pii: S0730-725X(19)30774-X
doi: 10.1016/j.mri.2020.03.002
pmc: PMC7237274
mid: NIHMS1579140
pii:
doi:
Substances chimiques
KRAS protein, human
0
ALK protein, human
EC 2.7.10.1
Anaplastic Lymphoma Kinase
EC 2.7.10.1
EGFR protein, human
EC 2.7.10.1
ErbB Receptors
EC 2.7.10.1
Proto-Oncogene Proteins p21(ras)
EC 3.6.5.2
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
49-56Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA013330
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA033572
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA209978
Pays : United States
Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest All authors declared that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Sci Rep. 2017 Jan 31;7:41674
pubmed: 28139704
Cancer Discov. 2017 Aug;7(8):818-831
pubmed: 28572459
Med Image Anal. 2011 Apr;15(2):267-82
pubmed: 21233004
N Engl J Med. 2018 Jan 11;378(2):113-125
pubmed: 29151359
Magn Reson Med. 1999 Dec;42(6):1072-81
pubmed: 10571928
Cancer Res. 2017 Nov 1;77(21):e104-e107
pubmed: 29092951
Eur J Cancer. 2012 Mar;48(4):441-6
pubmed: 22257792
Transl Oncol. 2018 Feb;11(1):94-101
pubmed: 29216508
Lung Cancer. 2015 Apr;88(1):108-11
pubmed: 25682925
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
IEEE Trans Med Imaging. 2010 Jan;29(1):196-205
pubmed: 19923044
Sci Rep. 2015 Aug 17;5:13087
pubmed: 26278466
Magn Reson Med. 2016 Nov;76(5):1410-1419
pubmed: 26621795
Handb Clin Neurol. 2018;149:3-23
pubmed: 29307359
Conf Proc IEEE Eng Med Biol Soc. 2017 Jul;2017:493-496
pubmed: 29059917
Radiology. 2014 Feb;270(2):320-5
pubmed: 24471381
Front Aging Neurosci. 2017 Oct 06;9:329
pubmed: 29056906
Nat Commun. 2014 Jun 03;5:4006
pubmed: 24892406
Neuroimage Clin. 2014 Aug 15;6:9-19
pubmed: 25379412
Bioinformatics. 2005 Aug 1;21(15):3301-7
pubmed: 15905277
MAGMA. 2018 Apr;31(2):285-294
pubmed: 28939952
Clin Lung Cancer. 2016 Sep;17(5):441-448.e6
pubmed: 27017476
Curr Oncol. 2013 Aug;20(4):e300-6
pubmed: 23904768
Eur Radiol. 2016 Jan;26(1):32-42
pubmed: 25956936
Neuro Oncol. 2015 Feb;17(2):296-302
pubmed: 25053852
IEEE Trans Pattern Anal Mach Intell. 2005 Aug;27(8):1226-38
pubmed: 16119262
Cureus. 2016 Feb 26;8(2):e513
pubmed: 27026837
Neuroimage. 2006 Jul 1;31(3):1116-28
pubmed: 16545965
Ther Adv Med Oncol. 2017 Dec;9(12):781-796
pubmed: 29449898
Cureus. 2016 Apr 25;8(4):e584
pubmed: 27226944